Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Orexigen Therapeutics has priced the public offering of 7 million shares of common stock at $11 per share. All shares are being offered by Orexigen.
Subscribe to our email newsletter
In addition, Orexigen has granted the underwriters a 30-day option to purchase an additional 1.05 million shares to cover overallotments, if any.
Merrill Lynch & Co. acted as sole book-running manager and Leerink Swann acted as co-lead manager for the offering. JMP Securities, Lazard Capital Markets, Canaccord Adams and Natixis Bleichroeder acted as co-managers for the offering.